Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 12/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.34 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3922542 | 0.91 | GRIN2B (0.40) | GRIN2BVCPUSP30CYP11B2 | |
| SCHEMBL3923646 | 0.85 | VCP (0.35) | GRIN2BVCPUSP30CCNE2CCNA2 | |
| SCHEMBL3924645 | 0.85 | CCNE2 (0.45) | VCPUSP30CCNE2CCNA2CCNE1 | |
| SCHEMBL3922547 | 0.85 | VCP (0.37) | GRIN2BVCPUSP30CCNE2CCNA2 | |
| SCHEMBL3924389 | 0.82 | MAPK8 (0.40) | CCNE2CCNA2CCNE1CDK2CCNA1 | |
| SCHEMBL3924760 | 0.78 | HRH4 (0.43) | CCNE2CCNA2CCNE1CDK2CCNA1 | |
| SCHEMBL5948116 | 0.77 | USP30 (0.44) | USP30PIM1 | |
| SCHEMBL5948011 | 0.76 | CCNE1 (0.48) | PIM1CCNE2CCNA2CCNE1CDK2 | |
| SCHEMBL3935077 | 0.76 | MAP3K5 (0.41) | CCNE2CCNA2CCNE1CDK2CCNA1 | |
| SCHEMBL3927808 | 0.74 | NPC1 (0.36) | CCNE2CCNA2CCNE1CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2041118-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2009-04-01 | — | — | EP | claimed |
| WO-2007114827-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2007-10-11 | — | — | WO | claimed |
| US-20060247263-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2006-11-02 | — | — | US | claimed |
| EP-2041118-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2009-04-01 | — | — | EP | disclosed |
| WO-2007114827-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| US-20060247263-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247263-A1 | Substituted heterocyclic compounds and methods of use | MAPT, IAPP, MYLK2 | GRIN2B 1353/4885VCP 1448/4885USP30 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.